Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review

This article was originally published in The Tan Sheet

Executive Summary

Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.

You may also be interested in...



Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share

Children's Flonase, like Children's Nasacort, is the same formulation and is indicated for the same overall age groups as the original product, but its labeling includes additional detail for use by children.

Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share

Children's Flonase, like Children's Nasacort, is the same formulation and is indicated for the same overall age groups as the original product, but its labeling includes additional detail for use by children.

Clarion Brands Argues NAD Turns Deaf Ear To Tinnitus Claims Review

Clarion Brands appeals NAD’s recommendations to discontinue a testimonial and other claims that convey the message its Lipo-Flavonoid Plus substantially reduces or eliminates tinnitus and the symptoms of Ménière’s disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel